AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — FY2013 Earnings Presentation

21 slides from AMAG Pharmaceuticals's earnings presentation, Feb 6, 2014

  1. Slide 1: AMAG Pharmaceuticals 2013 Financial Results

    AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, MA 02451 o 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES. AMAG Pharmaceuticals 2013 Financial Results February 6, 2014

  2. Slide 2: Forward Looking Statements

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Forward Looking Statements 1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do n

  3. Slide 3: Agenda

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Agenda Topic Speaker Opening Remarks Bill Heiden, CEO 2013 Financial Highlights Frank Thomas, COO Commercial Performance, Expansion Opportunities and Business Development Bill Heiden, CEO 2014 Financial Outlook Frank Thomas, COO Closin

  4. Slide 4: Mission: Build a Profitable, Multi-product Specialty Pharmaceutical Company

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Mission: Build a Profitable, Multi-product Specialty Pharmaceutical Company Commercial Infrastructure Focus on Hematology/Oncology, Hospital and Nephrology Strong Balance Sheet Experienced Management Team Feraheme® U.S. CKD Business Fe

  5. Slide 5: 2013 Achievements

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. 2013 Achievements • Outstanding 2013 financial performance Feraheme revenue +28% vs. 2012 Operating expenses -7% vs. 2012 Net loss -43% vs. 2012 • Record-breaking Feraheme performance In-market physician demand +20% vs. 2012 Evolution

  6. Slide 6: Feraheme 2013 Performance

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Feraheme 2013 Performance 5 Net ex-factory sales* ($ in millions) * Excludes the impact of changes in estimates made to product returns and Medicaid reserves in 2012 and 2013

  7. Slide 7: Outstanding 2013 Results

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Outstanding 2013 Results 6 * Includes the recognition of $18 million in milestones ** Includes the upfront costs of the MuGard licensing transaction and $2.9 million of restricted cash as of 12/31/13. *** Excludes the following non-cas

  8. Slide 8: Growing: Drive revenue growth of Feraheme

    ROWING UILDING & i / a¢ GROWING & amag * Drive revenue growth of Feraheme

  9. Slide 9: Demand Growth by Segment

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Demand Growth by Segment 8 2013 Results 20% increase in Feraheme provider demand 113 evolution index Source: IMS Health Data.

  10. Slide 10: U.S. IV Iron Market: Competitive Landscape

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. U.S. IV Iron Market: Competitive Landscape 9 *Aggregate of Ferrlecit Brand + Generic Ferric Gluconate Source: IMS DDD Data thru week ending 12/20/13 2013 Share of ~850,000 Gram Non-dialysis Market

  11. Slide 11: Today's Commercial Objective: Increase Share of Current CKD IV Iron Market

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Today’s Commercial Objective: Increase Share of Current CKD IV Iron Market 10 Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States

  12. Slide 12: 2014: U.S. IDA Label Expansion

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. 2014: U.S. IDA Label Expansion 11 Value of IDA in the US* •Leverage strong market position in IDA-CKD •Five Orange Book listed patents •Manufacturing and other proprietary know-how •Large market opportunity *If regulatory approval is p

  13. Slide 13: Potential IDA Label Expansion: Gain Additional Share of IV Iron Market

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. 12 Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digesti

  14. Slide 14: Opportunity: Grow U.S. IV Iron Market

    Copyright © 2014 AMAG Pharmaceuticals. All Rights Reserved. Opportunity: Grow U.S. IV Iron Market 13 IV Iron IDA* IV Iron IDA-CKD 4,000,000 patients diagnosed with IDA placed on oral iron therapy IV Iron IDA-CKD IV Iron IDA* Oral Iron IDA* Oral Iron IDA-CKD *If regulatory approval is pursued and rec

  15. Slide 15: Takeda's Feraheme in Europe

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Takeda’s in Europe 14 Double-digit tiered royalties on all Takeda sales; additional potential milestones

  16. Slide 16: MuGard's Road to Success in 2014

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. MuGard’s Road to Success in 2014 15 MuGard is a prescription oral rinse for the management of oral mucositis

  17. Slide 17: Building: Expand our product portfolio

    BUILDING •Build our future by expanding our product portfolio

  18. Slide 18: Targeted Business Development

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. Targeted Business Development 17 Financial •Similarly sized (or smaller) specialty company •Eliminate overlapping infrastructure and increase EBITDA •Examine transactions to optimize after-tax cash flows Bulls-Eye •Hem/onc or hospital

  19. Slide 19: 2014 Financial Outlook

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. 2014 Financial Outlook ($ in millions) Projections* Change from 2013 (calculated at midpoint of 2014 range) Total revenues $88 - $100 +16% U.S. Feraheme sales, net $75 - $85 +12% Feraheme COGS (% of Feraheme global net sales) 14% - 16%

  20. Slide 20: 2014 Goals

    Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved. 2014 Goals • Maximize Feraheme opportunities Drive market share and market growth within current U.S. IDA-CKD indication Optimize net revenue per gram Potential label expansion: IDA (non-CKD) oral iron failures - Expected E.U. action –

  21. Slide 21: Well positioned for success in 2014 and beyond

    AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, MA 02451 o 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES. Well positioned for success in 2014. . . and beyond.

AMAG Pharmaceuticals — FY2013 Earnings Presentation on 6ix